$6.65
0[0.00%]
At close: May 15
$6.65
0[0.00%]
After Hours: 5:25PM EDT
Nuvectis Pharma
(NASDAQ:NVCT)Nuvectis Pharma Stock (NASDAQ:NVCT), Analyst Ratings, Price Targets, Predictions
Nuvectis Pharma Inc has a consensus price target of $21, established from looking at the 7 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co. on May 8, 2024, September 15, 2023, and March 7, 2023. With an average price target of $21 between HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co., there's an implied 215.79% upside for Nuvectis Pharma Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Ladenburg Thalmann
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Nuvectis Pharma
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/08/2024 | Buy Now | 215.79% | HC Wainwright & Co. | Joseph Pantginis | → $21 | Reiterates | Buy → Buy | Get Alert |
| 09/15/2023 | Buy Now | 215.79% | HC Wainwright & Co. | Joseph Pantginis | → $21 | Reiterates | Buy → Buy | Get Alert |
| 03/07/2023 | Buy Now | 215.79% | HC Wainwright & Co. | Joseph Pantginis | → $21 | Reiterates | → Buy | Get Alert |
| 02/10/2023 | Buy Now | 215.79% | HC Wainwright & Co. | Joseph Pantginis | → $21 | Reiterates | → Buy | Get Alert |
| 07/13/2022 | Buy Now | 215.79% | Ladenburg Thalmann | Aydin Huseynov | → $21 | Initiates | → Buy | Get Alert |
| 05/10/2022 | Buy Now | 215.79% | HC Wainwright & Co. | Joseph Pantginis | $14 → $21 | Maintains | Buy | Get Alert |
| 03/02/2022 | Buy Now | 110.53% | HC Wainwright & Co. | Joseph Pantginis | → $14 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Nuvectis Pharma (NVCT)?
The latest price target for Nuvectis Pharma (NASDAQ: NVCT) was reported by HC Wainwright & Co. on May 8, 2024. The analyst firm set a price target for $21.00 expecting NVCT to rise to within 12 months (a possible 215.79% upside). 2 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Nuvectis Pharma (NVCT)?
The latest analyst rating for Nuvectis Pharma (NASDAQ: NVCT) was provided by HC Wainwright & Co., and Nuvectis Pharma reiterated their buy rating.
When was the last upgrade for Nuvectis Pharma (NVCT)?
There is no last upgrade for Nuvectis Pharma.
When was the last downgrade for Nuvectis Pharma (NVCT)?
There is no last downgrade for Nuvectis Pharma.
When is the next analyst rating going to be posted or updated for Nuvectis Pharma (NVCT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Nuvectis Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Nuvectis Pharma was filed on May 8, 2024 so you should expect the next rating to be made available sometime around May 8, 2025.
Is the Analyst Rating Nuvectis Pharma (NVCT) correct?
While ratings are subjective and will change, the latest Nuvectis Pharma (NVCT) rating was a reiterated with a price target of $0.00 to $21.00. The current price Nuvectis Pharma (NVCT) is trading at is $6.65, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.